Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIb trial

被引：2

作者：

Ettrich, T. ^{[1
]}

Perkofer, L. ^{[1
]}

Berger, A. W. ^{[1
]}

Guethle, M. ^{[1
]}

Behl, S. ^{[2
]}

Zipprich, A. ^{[2
]}

Woerns, M. A. ^{[3
]}

Waldschmidt, D. T. ^{[4
]}

Belle, S. ^{[5
]}

Michl, P. ^{[2
]}

Seufferlein, T. ^{[1
]}

Dollinger, M. M. ^{[1
]}

机构：

[1] Univ Ulm, Internal Med 1, D-89069 Ulm, Germany

[2] Univ Halle Wittenberg, Internal Med 1, D-06108 Halle, Germany

[3] Johannes Gutenberg Univ Mainz, Internal Med 1, D-55122 Mainz, Germany

[4] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany

[5] Mannheim Univ Hosp, Internal Med 2, Mannheim, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31279-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2363

引用

页码：S457 / S457

页数：1

共 50 条

[1] Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Abou-Alfa, Ghassan K.
Johnson, Philip
Knox, Jennifer J.
Capanu, Marinela
Davidenko, Irina
Lacava, Juan
Leung, Thomas
Gansukh, Bolorsukh
Saltz, Leonard B.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (19): : 2154 - 2160
[2] Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Bi, Feng
Qin, Shukui
Gu, Shanzhi
Bai, Yuxian
Chen, Zhendong
Wang, Zishu
Ying, Jieer
Lu, Yinying
Meng, Zhiqiang
Pan, Hongming
Yang, Ping
Zhang, Helong
Chen, Xi
Xu, Aibing
Liu, Xiufeng
Meng, Qiu
Wu, Liqing
Chen, Feng
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.
Ikeda, Masafumi
Shimizu, Satoshi
Sato, Tosiya
Morimoto, Manabu
Inaba, Yoshitaka
Kojima, Yasushi
Hagihara, Atsushi
Kudo, Masatoshi
Nakamori, Shoji
Kaneko, Shuichi
Sugimoto, Rie
Tahara, Toshiyuki
Ohmura, Takumi
Yasui, Kohichiroh
Sato, Keiko
Ishii, Hiroshi
Furuse, Junji
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
Abou-Alfa, Ghassan K.
Shi, Qian
Knox, Jennifer J.
Kaubisch, Andreas
Niedzwiecki, Donna
Posey, James
Tan, Benjamin R., Jr.
Kavan, Petr
Goel, Rakesh
Lammers, Philip E.
Bekaii-Saab, Tanios S.
Tam, Vincent C.
Rajdev, Lakshmi
Kelley, Robin K.
El Dika, Imane
Zemla, Tyler
Potaracke, Ryan, I
Balletti, Jennifer
El-Khoueiry, Anthony B.
Harding, James H.
Suga, Jennifer M.
Schwartz, Lawrence H.
Goldberg, Richard M.
Bertagnolli, Monica M.
Meyerhardt, Jeffrey
O'Reilly, Eileen M.
Venook, Alan P.
JAMA ONCOLOGY, 2019, 5 (11) : 1582 - 1588
[5] SORAFENIB PLUS TACE FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA - FINAL RESULTS OF THE SOCRATES TRIAL
Erhardt, A.
Kolligs, F. T.
Dollinger, M.
Schott, E.
Wege, H.
Bitzer, M.
Gog, C.
Raedle, J.
Schuchmann, M.
Walter, C.
Blondin, D.
Ohmann, C.
Haeussinger, D.
JOURNAL OF HEPATOLOGY, 2011, 54 : S35 - S35
[6] Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Yau, Thomas
Park, Joong-Won
Finn, Richard S.
Cheng, Ann-Lii
Mathurin, Philippe
Edeline, Julien
Kudo, Masatoshi
Harding, James J.
Merle, Philippe
Rosmorduc, Olivier
Wyrwicz, Lucjan
Schott, Eckart
Choo, Su Pin
Kelley, Robin Kate
Sieghart, Wolfgang
Assenat, Eric
Zaucha, Renata
Furuse, Junji
Abou-Alfa, Ghassan K.
El-Khoueiry, Anthony B.
Melero, Ignacio
Begic, Damir
Chen, Gong
Neely, Jaclyn
Wisniewski, Tami
Tschaika, Marina
Sangro, Bruno
LANCET ONCOLOGY, 2022, 23 (01): : 77 - 90
[7] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han-Chong
Gorbunova, Vera
Eskens, Ferry A. L. M.
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El-Nowiem, Saied
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
[8] Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
Kelley, Robin Kate
Rimassa, Lorenza
Cheng, Ann-Lii
Kaseb, Ahmed
Qin, Shukui
Zhu, Andrew X.
Chan, Stephen L.
Melkadze, Tamar
Sukeepaisarnjaroen, Wattana
Breder, Valery
Verset, Gontran
Gane, Edward
Borbath, Ivan
Rangel, Jose David Gomez
Ryoo, Baek-Yeol
Makharadze, Tamta
Merle, Philippe
Benzaghou, Fawzi
Banerjee, Kamalika
Hazra, Saswati
Fawcett, Jonathan
Yau, Thomas
LANCET ONCOLOGY, 2022, 23 (08): : 995 - 1008
[9] Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial
Motzer, R.
Nosov, D.
Eisen, T.
Bondarenko, I.
Lesovoy, V.
Lipatov, O.
Tomczak, P.
Lyulko, O.
Alyasova, A.
Harza, M.
Kogan, M.
Alexeev, B. Y.
Sternberg, C. N.
Szczylik, C.
Zhang, J.
Strahs, A.
Esteves, B.
Slichenmyer, W.
Berkenblit, A.
Hutson, T. E.
BJU INTERNATIONAL, 2012, 110 : 14 - 14
[10] Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
Ikeda, M.
Shimizu, S.
Sato, T.
Morimoto, M.
Kojima, Y.
Inaba, Y.
Hagihara, A.
Kudo, M.
Nakamori, S.
Kaneko, S.
Sugimoto, R.
Tahara, T.
Ohmura, T.
Yasui, K.
Sato, K.
Ishii, H.
Furuse, J.
Okusaka, T.
ANNALS OF ONCOLOGY, 2016, 27 (11) : 2090 - 2096

← 1 2 3 4 5 →